# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce complement system
- describe C3 and its role
- discuss CRIg and its function
- summarize related art

## SUMMARY OF THE INVENTION

- introduce crystal structure of CRIg
- describe crystal structure of C3b and C3c in complex with CRIg
- define CRIg crystal
- describe CRIg crystal properties
- define CRIg:C3b complex crystal
- describe CRIg:C3b complex crystal properties
- outline invention aspects

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

### Definitions

- define technical terms
- define CRIg and variants
- define native sequence CRIg
- define CRIg variant
- define extracellular domain
- define percent amino acid sequence identity
- define percent nucleic acid sequence identity
- define isolated nucleic acid molecule
- define isolated CRIg polypeptide-encoding nucleic acid molecule
- define complement-associated disease
- define complement-associated eye condition
- define inflammatory disease
- define T-cell mediated disease
- list examples of immune-related and inflammatory diseases
- define tumor
- define cancer
- define treatment
- define pathology
- define mammal
- define administration
- define cytokine
- define therapeutically effective amount
- define control sequences
- define stringency
- define biological activity
- define CRIg agonist
- define antagonist
- define small molecule
- define antibody
- describe native antibodies
- describe antibody fragments
- define Fv
- describe Fab and F(ab')2
- describe light chains
- describe immunoglobulin classes
- define monoclonal antibody
- describe chimeric and humanized antibodies
- define single-chain Fv
- define diabodies
- define isolated polypeptide
- define label, solid phase, liposome, immunoadhesin, chronic, intermittent, and subject

### MODES OF CARRYING OUT THE INVENTION

- introduce conventional techniques
- motivate crystal structure determination
- describe x-ray crystallography
- discuss crystallization methods
- introduce CRIg crystal structure
- describe C3b:CRIg complex structure
- describe C3c:CRIg complex structure
- detail C3b structure
- describe conformational change upon activation
- locate CRIg binding site
- describe binding interface
- validate structure-function findings
- introduce screening assays
- describe agonist and antagonist design
- detail immunoadhesins
- describe peptide mimetics
- outline screening and identification methods
- describe solid phase peptide synthesis
- describe protective groups for carboxyl functional group
- describe protection of specific amino acids
- describe sources of blocked amino acids
- describe peptide cleavage and purification
- describe application of CRIg antagonists in cancer treatment
- describe use of CRIg antagonists in immunoadjuvant therapy
- describe macrophages in tumor eradication
- describe antibodies as CRIg antagonists
- describe types of antibodies
- describe preparation of monoclonal antibodies
- describe immunizing agent and fusion of lymphocytes
- describe selection of hybridoma cells
- describe purification of monoclonal antibodies
- describe recombinant DNA methods for making monoclonal antibodies
- describe preparation of monovalent antibodies
- describe humanized antibodies
- describe bispecific antibodies
- describe heteroconjugate antibodies
- describe modification of antibodies for effector function
- describe immunoconjugates with cytotoxic agents
- describe conjugation of antibody to receptor
- outline in vitro and in vivo assays for CRIg
- highlight utility of CRIg in preventing/treating complement-associated diseases
- list examples of complement-associated diseases
- describe age-related macular degeneration (AMD)
- highlight CRIg's utility in treating high-risk AMD
- list examples of inflammatory conditions
- describe systemic lupus erythematosus
- describe rheumatoid arthritis
- describe juvenile chronic arthritis
- describe spondyloarthropathies
- describe systemic sclerosis (scleroderma)
- describe idiopathic inflammatory myopathies
- describe Sjögren's syndrome
- describe systemic vasculitis
- describe sarcoidosis
- describe autoimmune hemolytic anemia and thrombocytopenia
- outline potential therapeutic uses of CRIg
- describe animal models for arthritis
- describe animal models for psoriasis
- describe transgenic animal models
- describe techniques for producing transgenic animals
- describe monitoring transgene expression
- describe blocking experiments
- describe knockout animals
- describe characterizing knockout animals
- describe model of asthma
- describe contact hypersensitivity model
- describe graft-versus-host disease model
- describe skin allograft rejection model
- describe delayed type hypersensitivity model
- describe EAE model
- describe age-related macular degeneration model
- describe myocardial ischemia-reperfusion model
- describe diabetic retinopathy model
- describe pharmaceutical compositions

### Example 1

- describe production and purification of mature human CRIg protein
- describe crystallization of CRIg
- describe data collection, structure solution and refinement of CRIg
- summarize structure determination of CRIg
- describe overall structure of C3b
- describe conformational changes upon C3 activation
- discuss differences between C3S and C3F allotypes
- describe TED module in C3b
- describe CRIg binding to β-chain of C3b and C3c
- describe binding interface between CRIg and C3c or C3b
- discuss importance of MG3 domain in gating CRIg binding
- describe functional validation of binding interface using CRIg mutants
- summarize binding parameters in Table 1

### CRIg Variants

- describe generation and testing of CRIg mutants

### Example 3

- describe CRIg binding to C3b inhibiting alternative pathway of complement

### Example 4

- introduce arthritis model
- describe materials and methods
- measure cytokine concentration
- perform ELISA analysis
- present results

### Example 5

- describe decay acceleration assays
- prepare C3b-C4b and C3b-C3b dimers
- perform binding and competition assays
- determine CRIg's mechanism of action
- present results

